These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12324500)

  • 1. Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation.
    Fenyvesi T; Joerg I; Harenberg J
    Clin Chem; 2002 Oct; 48(10):1791-4. PubMed ID: 12324500
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time.
    Fenyvesi T; Jörg I; Weiss C; Harenberg J
    Thromb Res; 2003; 111(1-2):89-94. PubMed ID: 14644085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method.
    Fenyvesi T; Jörg I; Harenberg J
    Pathophysiol Haemost Thromb; 2002; 32(4):174-9. PubMed ID: 12759518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro effect of melagatran and lepirudin on clot-bound thrombin.
    Lebrazi J; Elalamy I; Samama MM
    Thromb Res; 2003 Jun; 110(4):249-52. PubMed ID: 14512090
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring of anticoagulant effects of direct thrombin inhibitors.
    Fenyvesi T; Jörg I; Harenberg J
    Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the pharmacology of thrombin inhibitors.
    Adams TE; Everse SJ; Mann KG
    J Thromb Haemost; 2003 May; 1(5):1024-7. PubMed ID: 12871372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin-directed inhibitors: pharmacology and clinical use.
    White CM
    Am Heart J; 2005 Jan; 149(1 Suppl):S54-60. PubMed ID: 15644794
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values.
    Gosselin RC; Dager WE; King JH; Janatpour K; Mahackian K; Larkin EC; Owings JT
    Am J Clin Pathol; 2004 Apr; 121(4):593-9. PubMed ID: 15080313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
    Elg M; Gustafsson D; Deinum J
    Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
    Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
    BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of ex vivo anticoagulants on whole blood platelet aggregation.
    Kalb ML; Potura L; Scharbert G; Kozek-Langenecker SA
    Platelets; 2009 Feb; 20(1):7-11. PubMed ID: 19172515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
    Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
    Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hirudin in heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
    Koestenberger M; Cvirn G; Gallistl S; Muntean W
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors.
    Gurm HS; Bhatt DL
    Am Heart J; 2005 Jan; 149(1 Suppl):S43-53. PubMed ID: 15644793
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
    Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
    Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
    Olah Z; Szarvas M; Bereczky Z; Kerenyi A; Kappelmayer J; Boda Z
    Arch Pathol Lab Med; 2013 Jul; 137(7):967-73. PubMed ID: 23808469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.